We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » STUDY: SSRIS MAY INCREASE SUICIDE RISK IN SENIORS

STUDY: SSRIS MAY INCREASE SUICIDE RISK IN SENIORS

May 1, 2006

Older patients taking selective serotonin reuptake inhibitors, or SSRIs -- a class of antidepressants that includes Prozac, Paxil and Zoloft -- may be more likely to have intense suicidal thoughts or commit suicide, according to data published in the American Journal of Psychiatry. The study, conducted by researchers at the Institute for Clinical Evaluative Sciences in Toronto, showed that the suicide rate among seniors taking SSRIs was nearly five times higher than among those who were treated with other forms of antidepressants.

The study was conducted using patient prescription data, physician billing claims, hospitalization data and coroner's records for Ontario residents 66 and older between 1992 and 2000. There were about 1.2 million seniors whose information was examined, including 1,329 suicide cases. Among seniors who had committed suicide, more than two-thirds (907 people) had received no treatment. In the nine-year period, 73 patients taking SSRIs committed suicide, as did 349 patients taking other antidepressants.

David Juurlink, the study's lead author, noted, however, that it is difficult to distinguish the role of depression itself from the possible effects of the medication, In patients with major depression, he said, the "hazards of undertreatment almost certainly outweigh the risks of therapy."

In Canada, he added, there are approximately 16 million SSRI prescriptions issued annually, at a total cost of more than $1 billion.

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing